Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:APTNASDAQ:CTCXNASDAQ:CTSONYSE:VAPO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPTAlpha Pro Tech$4.70+0.1%$4.50$4.06▼$6.44$50.90M0.330,975 shs2,527 shsCTCXCarmell$3.74+26.4%$0.76$0.17▼$2.65$78.19M0.513.76 million shs1.17 million shsCTSOCytosorbents$0.87+5.5%$0.96$0.70▼$1.61$54.16M1.17146,408 shs5,048 shsVAPOVapotherm$2.17$2.16$0.70▼$3.44$13.58M-1.11N/A51,531 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPTAlpha Pro Tech+2.18%+3.08%+8.06%-13.15%-8.75%CTCXCarmell0.00%-14.05%+1,543.75%+1,019.15%0.00%CTSOCytosorbents-2.38%-3.42%-26.79%-22.64%-8.89%VAPOVapotherm0.00%0.00%0.00%0.00%+161.32%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPTAlpha Pro TechN/AN/AN/AN/AN/AN/AN/AN/ACTCXCarmellN/AN/AN/AN/AN/AN/AN/AN/ACTSOCytosorbents1.8281 of 5 stars3.52.00.00.02.50.00.6VAPOVapothermN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPTAlpha Pro Tech 0.00N/AN/AN/ACTCXCarmell 0.00N/AN/AN/ACTSOCytosorbents 3.00Buy$5.50570.73% UpsideVAPOVapotherm 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest VAPO, CTSO, CTCX, and APT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2025CTSOCytosorbentsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.005/15/2025CTSOCytosorbentsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$1.00 ➝ $1.005/2/2025CTSOCytosorbentsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.004/3/2025CTSOCytosorbentsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$1.00 ➝ $1.004/1/2025CTSOCytosorbentsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00(Data available from 5/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPTAlpha Pro Tech$58.18M0.88$0.37 per share12.80$5.29 per share0.89CTCXCarmell$32.84K1,674.23N/AN/A$1.07 per share2.46CTSOCytosorbents$35.33M1.45N/AN/A$0.52 per share1.58VAPOVapotherm$68.67M0.20N/AN/A($9.01) per share-0.24Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPTAlpha Pro Tech$4.19M$0.3712.68∞N/A6.99%6.70%5.76%N/ACTCXCarmell-$15.44MN/A0.00∞N/AN/A-217.50%-50.22%N/ACTSOCytosorbents-$28.51M-$0.28N/AN/AN/A-49.47%-118.54%-42.31%8/12/2025 (Estimated)VAPOVapotherm-$58.19M-$8.51N/A∞N/A-76.74%N/A-68.08%N/ALatest VAPO, CTSO, CTCX, and APT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025CTSOCytosorbents-$0.08-$0.06+$0.02-$0.02$9.01 million$8.73 million3/31/2025Q4 2024CTSOCytosorbents-$0.07-$0.03+$0.04-$0.14$10.09 million$9.20 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPTAlpha Pro TechN/AN/AN/AN/AN/ACTCXCarmellN/AN/AN/AN/AN/ACTSOCytosorbentsN/AN/AN/AN/AN/AVAPOVapothermN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPTAlpha Pro TechN/A19.0011.21CTCXCarmellN/A0.310.29CTSOCytosorbents1.061.971.58VAPOVapothermN/A0.250.09Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPTAlpha Pro Tech22.69%CTCXCarmell24.22%CTSOCytosorbents32.87%VAPOVapotherm43.08%Insider OwnershipCompanyInsider OwnershipAPTAlpha Pro Tech15.00%CTCXCarmell29.00%CTSOCytosorbents7.30%VAPOVapotherm15.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPTAlpha Pro Tech12010.86 million9.46 millionOptionableCTCXCarmell1420.91 million14.84 millionNot OptionableCTSOCytosorbents22062.61 million51.07 millionOptionableVAPOVapotherm2906.26 million5.27 millionNo DataVAPO, CTSO, CTCX, and APT HeadlinesRecent News About These CompaniesNew Study Confirms Vapotherm's Unicorn™ Cannula Provides Comparable Efficacy at Lower Flow RatesMay 20, 2025 | finance.yahoo.comGlobal High-Flow Oxygen Therapy Devices Market Set to Reach USD 1,567.2 Million by 2033 Amid Rising Demand for Respiratory Care Solutions | FMIOctober 25, 2024 | fmiblog.comGlobal Active Humidifier Devices Market Projects Modest Decline Amid Shifting Respiratory Care Landscape | FMIOctober 25, 2024 | fmiblog.comDecline Looms Over Global High Flow Nasal Cannula Market to reach USD 1,063.0 Million by 2034: A Call for Innovation and Adaptation | FMIOctober 21, 2024 | fmiblog.comGlobal Endobronchial Valves Market Expected to Experience Strong Growth by 2031 | Exactitude ConsultancySeptember 24, 2024 | finance.yahoo.comVapotherm, Inc.: Vapotherm Announces Closing of MergerSeptember 20, 2024 | finanznachrichten.deVapotherm Announces Closing of MergerSeptember 20, 2024 | prnewswire.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VAPO, SGE, RPHM, SQSP on Behalf of ShareholdersAugust 30, 2024 | stockhouse.comVAPO Stock Earnings: Vapotherm Reported Results for Q2 2024August 13, 2024 | msn.comVapotherm Reports Second Quarter 2024 Financial ResultsAugust 12, 2024 | prnewswire.comPLPL Plandaí Biotechnology, Inc.July 28, 2024 | seekingalpha.comVA20.SG,0P0001F4D7,0 (VA20.SG)July 23, 2024 | finance.yahoo.comSHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates Merger of Vapotherm, Inc. - VAPOJuly 9, 2024 | prnewswire.comSHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates Merger of Vapotherm, Inc. – VAPOJuly 8, 2024 | globenewswire.comThe Schall Law Firm Is Performing A Scrutiny Into Vapotherm Inc And Welcomes Investors Of VAPO To EngageJuly 1, 2024 | accesswire.comThe Schall Law Firm Is Carrying Out An Inquiry Into Vapotherm Inc And Requests Investors Of VAPO To Be Part Of ItJune 30, 2024 | accesswire.comThe Schall Law Firm Is Undertaking An Investigation Into Vapotherm Inc And Invites Investors Of VAPO To JoinJune 29, 2024 | accesswire.comThe Schall Law Firm Is Leading An Investigation Into Vapotherm Inc And Invites Investors Of VAPO To JoinJune 28, 2024 | accesswire.comThe Schall Law Firm Is Conducting A Probe Into Vapotherm Inc And Encourages VAPO Investors To ParticipateJune 27, 2024 | accesswire.comThe Schall Law Firm Is Conducting A Probe Into Vapotherm Inc And Encourages Investors Of VAPO To ParticipateJune 26, 2024 | accesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVAPO, CTSO, CTCX, and APT Company DescriptionsAlpha Pro Tech NYSE:APT$4.70 +0.01 (+0.11%) As of 11:58 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Alpha Pro Tech, Ltd., together with its subsidiaries, develops, manufactures, and markets a range of disposable protective apparel, infection control, and building supply products in the United States and internationally. The company operates through Disposable Protective Apparel and Building Supply segments. The Disposable Protective Apparel segment provides shoe covers, bouffant caps, coveralls, frocks, lab coats, and gowns, hoods, as well as face masks and shields. The Building Supply segment offers construction weatherization products, such as housewrap and housewrap accessories, including window and door flashing, and seam tape, synthetic roof underlayment, and self-adhered roof underlayment, as well as other woven material. The company markets its products under the Alpha Pro Tech brand name, as well as under private labels. Its products are used primarily in cleanrooms; industrial safety manufacturing environments; health care facilities, such as hospitals, laboratories, and dental offices; building and re-roofing sites. The company distributes its products through a network of purchasing groups, distributors, and independent sales representatives, as well as through its sales and marketing force. Alpha Pro Tech, Ltd. was founded in 1983 and is headquartered in Markham, Canada.Carmell NASDAQ:CTCX$3.74 +0.78 (+26.35%) As of 05/29/2025Carmell Corporation operates as a bio-aesthetics company. The company utilizes Carmell Secretome to support skin and hair health. Its Carmell Secretome consists of growth factors and proteins extracted from allogeneic human platelets sourced from tissue banks. The company also developed a microemulsion formulation that enables delivery of lipophilic and hydrophilic ingredients without relying on the Foul Fourteen, 14 potentially harmful excipients that are commonly used by other companies to impart texture, stability, and other desirable physicochemical attributes to cosmetic products. In addition, the company is also developing a line of men's products and a line of topical haircare products. It has licensing agreement with Carnegie Mellon University to develop and commercialize biocompatible plasma-based plastics. The company was formerly known as Carmell Therapeutics Corporation and changed its name to Carmell Corporation in November 2023. Carmell Therapeutics Corporation was founded in 2008 and is headquartered in Pittsburgh, Pennsylvania.Cytosorbents NASDAQ:CTSO$0.86 +0.05 (+5.49%) As of 12:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.Vapotherm NYSE:VAPOVapotherm, Inc., a medical technology company, focuses on the development and commercialization of proprietary high velocity therapy products used to treat patients of various ages suffering from respiratory distress in the United States and internationally. The company offers High Velocity Therapy systems, such as HVT 2.0, Precision Flow Hi-VNI, Precision Flow Plus, and Precision Flow Classic which delivers non-invasive ventilatory support to patients by providing heated, humidified, and oxygenated air at a high velocity to treat patients through a small-bore nasal interface. It also provides companion products, including Vapotherm Transfer Unit, which allows patients to be transferred between care areas within the hospital or ambulate while on therapy; Q50 compressor that provides compressed air necessary to run the precision flow systems in areas of the hospital without access to a wall gas source; aerosol aeroneb adaptor to facilitate delivery of aerosolized solutions; aerosol disposable patient circuit that is designed to streamline the provision of continuous and intermittent delivery of aerosol solutions for patients; and tracheostomy adaptors that simplifies the connection of the High Velocity Therapy systems to a tracheostomy collar used to wean patients off mechanical ventilation. In addition, the company offers ProSoft cannula to provide gentle contact with the skin; and disposable products comprising single-use disposables and nasal interfaces, as well as Oxygen Assist Module, which helps clinicians maintain oxygen levels within a target range. Vapotherm, Inc. was founded in 1993 and is headquartered in Exeter, New Hampshire. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Taiwan Semiconductor: Time to Buy After Strong NVIDIA Results? Archer Aviation Stock Steadies After Short-Seller Report e.l.f. Beauty Sees Record Surge After Earnings, Rhode Deal Apple Stock Could Rally After Tariffs Are Blocked By Court Hormel Stock Near Lows, But Tariff Relief Could Boost Outlook Salesforce’s Stock Price Presents an Opportunity to Buy NVIDIA Will Set a New High Soon, Then Keep Rallying, Here’s Why Goodyear Stock Surges 28% in 2025: Is More Growth Ahead? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
